AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,322.50GBp
12:00pm EDT
Price Change (% chg)

-38.50p (-0.88%)
Prev Close
4,361.00p
Open
4,379.00p
Day's High
4,390.00p
Day's Low
4,319.50p
Volume
1,869,453
Avg. Vol
3,460,978
52-wk High
4,946.41p
52-wk Low
3,085.21p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.35
Market Cap (Mil.): £55,027.70
Shares Outstanding (Mil.): 1,262.56
Dividend: 116.80
Yield (%): 4.04

Financials

  AZN.L Industry Sector
P/E (TTM): 45.36 35.65 36.07
EPS (TTM): 0.96 -- --
ROI: 5.15 18.91 18.18
ROE: 9.37 19.67 19.05
Search Stocks

Pfizer leaves investors guessing on intentions for Astra

- Pfizer Inc , which in May abandoned its $118 billion bid for AstraZeneca Plc , on Tuesday left investors guessing whether it would renew its pursuit of its British rival, but said it was considering other deals. | Video

4:35pm EDT

UPDATE 3-Pfizer leaves investors guessing on intentions for Astra

(Adds CEO, CFO, analyst comments, details on experimental drugs, paragraphs 4-15)

4:24pm EDT

Deals of the day- Mergers and acquisitions

(Adds Pfizer, Nobel Biocare, Edison, Millhouse Capital, Bank of Cyprus)

4:07pm EDT

Pfizer leaves investors guessing on intentions for Astra

- Pfizer Inc , which in May abandoned its $118 billion bid to buy AstraZeneca Plc , on Tuesday left investors guessing whether it would renew its pursuit of its British rival, but said it was considering other deals.

12:51pm EDT

BRIEF-Pfizer says looking at other deals, declines comment on interest in AstraZeneca

July 29 - Pfizer Inc : * CEO, in investor conference call, says feels current company strategy "right on" despite revenue growth

11:15am EDT

Pfizer beats forecasts as oncology drugs grow

July 29 - Pfizer Inc, which in May officially abandoned its bid to buy British rival AstraZeneca Plc, reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.

7:28am EDT

REFILE-UPDATE 3-Microsoft targeted in apparent Chinese anti-trust probe

BEIJING, July 28 - Microsoft Corp appears to be the latest U.S. company targeted by China for anti-trust investigation after government officials paid sudden visits to the software firm's Chinese offices on Monday.

28 Jul 2014

AstraZeneca taps Roche, Qiagen for new blood-based cancer drug tests

LONDON - AstraZeneca has signed up Roche and Qiagen to develop two separate diagnostic tests, both using simple blood samples, to identify patients who will benefit from its lung cancer drugs.

28 Jul 2014

AstraZeneca taps Roche, Qiagen for new blood-based cancer drug tests

LONDON, July 28 - AstraZeneca has signed up Roche and Qiagen to develop two separate diagnostic tests, both using simple blood samples, to identify patients who will benefit from its lung cancer drugs.

28 Jul 2014

Pfizer's need for deal looms larger with earnings report

NEW YORK - Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.

28 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks